We read with interest the report by Leino et al. (1 ) As individuals working in university reference laboratories, we receive several telephone calls each week from physicians who are puzzled by the fact that the serum 25-OH-D concentration for their patients has not increased, or has even decreased, during treatment with vitamin D (sometimes large doses). These patients invariably received vitamin D 2 and were monitored for their 25-OH-D concentration with the Roche assay. Every time a verification measurement was done in our laboratories with the DiaSorin RIA, the concentration was typical (Ͼ75 nmol/L) and sometimes quite high (Ͼ200 nmol/L). As we recently reported (2 ), this situation not only generates useless and costly exploration of results but also produces a certain degree of anxiety in the patients. We are even aware of 2 patients in whom a malabsorption syndrome was suspected and an upper gastrointestinal endoscopy procedure was planned. Fortunately, the procedures were not performed after we explained to the physician that the absence of an increase in the serum 25-OH-D concentration was due to an analytical problem. Furthermore, a low 25-OH-D concentration measured with the Roche assay in a patient treated with vitamin D 2 may prompt a physician to prescribe large doses of vitamin D in a patient already replete with vitamin D, thus potentially causing toxic 25-OH-D concentrations to be attained. Finally, after discussing this issue with physicians, we came to realize that many physicians prescribing vitamin D are unaware of whether they have prescribed a drug containing vitamin D 2 or vitamin D 3 . We also realized that many of these physicians thought that vitamin D 2 was in fact 1,25-dihydroxyvitamin D. This confusion highlights the urgent need for providing clear and simple information about vitamin D immunoassays to the medical community.
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